TY - JOUR
AU - Carter, Ben
AU - Ramsay, Euan A.
AU - Short, Roxanna
AU - Goodison, Sarah
AU - Lumsden, Jane
AU - Khan, Amarah
AU - Braude, Philip
AU - Vilches-Moraga, Arturo
AU - Quinn, Terence J.
AU - McCarthy, Kathryn
AU - Hewitt, Jonathan
AU - Myint, Phyo Kyaw
AU - Bruce, Eilidh
AU - Einarsson, Alice
AU - McCrorie, Kirsty
AU - Aggrey, Ken
AU - Bilan, Jimmy
AU - Hartrop, Kerr
AU - Murphy, Caitlin
AU - McGovern, Aine
AU - Clini, Enrico
AU - Guaraldi, Giovanni
AU - Verduri, Alessia
AU - Bisset, Carly
AU - Alexander, Ross
AU - Kelly, Joanna
AU - Murphy, Caroline
AU - Mutasem, Tarik El Jichi
AU - Singh, Sandeep
AU - Paxton, Dolcie
AU - Harris, Will
AU - Moug, Susan J.
AU - Galbraith, Norman
AU - Bhatti, Emma
AU - Edwards, Jenny
AU - Duffy, Siobhan
AU - Espinoza, Maria Fernanda Ramon
AU - Kneen, Thomas
AU - Dafnis, Anna
AU - Allafi, Hala
AU - Vidal, Maria Narro
AU - Price, Angeline
AU - Pearce, Lyndsay
AU - Lee, Thomas C.
AU - Sangani, Shefali
AU - Garcia, Madeline
AU - Davey, Charlotte
AU - Jones, Sheila
AU - Lunstone, Kiah
AU - Cavenagh, Alice
AU - Silver, Charlotte
AU - Telford, Thomas
AU - Simmons, Rebecca
PY - 2022
DA - February
TI - Prognostic value of estimated glomerular filtration rate in hospitalised older patients (over 65) with COVID-19: a multicentre, European, observational cohort study
JO - BMC Geriatrics
VL - 22
IS - 1
DO - http://dx.doi.org/10.1186/s12877-022-02782-5
AB - Background: The reduced renal function has prognostic significance in COVID-19 and it has been linked to mortality in the general population. Reduced renal function is prevalent in older age and thus we set out to better understand its effect on mortality. Methods: Patient clinical and demographic data was taken from the COVID-19 in Older People (COPE) study during two periods (February–June 2020 and October 2020–March 2021, respectively). Kidney function on admission was measured using estimated glomerular filtration rate (eGFR). The primary outcomes were time to mortality and 28-day mortality. Secondary outcome was length of hospital stay. Data were analysed with multilevel Cox proportional hazards regression, and multilevel logistic regression and adjusted for individual patient clinical and demographic characteristics. Results: One thousand eight hundred two patients (55.0% male; median [IQR] 80 [73–86] years) were included in the study. 28-day mortality was 42.3% (n = 742). 48% (n = 801) had evidence of renal impairment on admission. Using a time-to-event analysis, reduced renal function was associated with increased in-hospital mortality (compared to eGFR ≥ 60 [Stage 1&amp;2]): eGFR 45–59 [Stage 3a] aHR = 1.26 (95%CI 1.02–1.55); eGFR 30–44 [Stage 3b] aHR = 1.41 (95%CI 1.14–1.73); eGFR 1–29 [Stage 4&amp;5] aHR = 1.42 (95%CI 1.13–1.80). In the co-primary outcome of 28-day mortality, mortality was associated with: Stage 3a adjusted odds ratio (aOR) = 1.18 (95%CI 0.88–1.58), Stage 3b aOR = 1.40 (95%CI 1.03–1.89); and Stage 4&amp;5 aOR = 1.65 (95%CI 1.16–2.35). Conclusion: eGFR on admission is a good independent predictor of mortality in hospitalised older patients with COVID-19 population. We found evidence of a dose-response between reduced renal function and increased mortality.
PB - Springer Nature
UR - http://eprints.gla.ac.uk/265263/
KW - Coronavirus (COVID-19)
ER